News for Health Professionals Archive - August 2012

August 1, 2012

• Hospira Reports Second-Quarter 2012 Results
• Bristol-Myers Squibb Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Amylin Pharmaceuticals, Inc.
• Welichem and Stiefel, a GSK company, complete the acquisition by Stiefel of the novel anti-inflammatory agent, WBI-1001
• Pfizer Study: Arthritis Pill Beats Standard Drug
• European Medicines Agency Sees Benefits of Interaction With Japanese Regulators
• Cell Therapeutics, Inc. (CTI) Readies Pixuvri European Launch and Start of Pacritinib Phase 3 Trial; Reports Second Quarter Financial Results and Milestones
• Shire Second Quarter Product Sales Up 16%
• AmeriSourceBergen Wins $18.5 Billion Express Scripts Contract
• Shire Shares Climb After 2Q Profit Report

August 2, 2012

• Teva Reports Second Quarter 2012 Results
• Pharming Announces Restructuring Plan
• Gilead Sciences Announces New Collaboration with Indian Partners to Reduce Manufacturing Cost and Improve Availability of Emtricitabine-Based Antiretroviral Therapy in Developing Countries
• Bristol-Myers Squibb Suspends Administration of Study Drug in Clinical Trial of Investigational NS5B Nucleotide for the Treatment of Hepatitis C
• Drug Combo Better for Common Type of Metastatic Breast Cancer, UCI-Led Study Finds
• Carl Icahn Issues Open Letter To Shareholders Of Forest Laboratories
• PhRMA Statement on Prescription Drug Costs
• Markey, House Dems Introduce Bill to Protect Human Subjects in Clinical Trials
• SEC Charges Bristol-Myers Squibb Executive With Insider Trading in Stock Options of Potential Acquisition Targets

August 3, 2012

• New Study Finds Generic Drugs Saved Consumers Over $1 Trillion
• Study Quantifies Impact of Pharmaceuticals on Enhanced Productivity
• BMS Exec Charged in Insider Trading
• Incyte Stumbles Despite Posting 2Q Profit
• Valeant Posts 2Q Loss but Revenue Grows 35 Percent

August 6, 2012

• Johnson & Johnson Reaches Risperdal Lawsuit Agreement
• Tekmira Provides Update on Collaboration With U.S. Government's TMT Program
• Novartis and University of Pennsylvania Form Broad-Based R&D Alliance to Advance Novel T-Cell Immunotherapies to Treat Cancer
• Astellas to Close Urogenix, North Carolina-based Urology Research Facility
• K-V Pharmaceutical Company Files Voluntary Petitions for Reorganization to Restructure Financial Obligations
• Mylan Launches Commercial Operations in India, Starting with a Broad, Innovative Portfolio of ARV Products to Treat HIV/AIDS
• SEC Opens Teva Bribery Probe
• Penn and Novartis Will Team on Cancer Research
• Court Grants Jury Trial For Failure To Warn Suit Against Drug Company
• Pluristem Therapeutics Climbs
• Life of Cancer Patient Suffering from Bone Marrow Failure Saved Following Treatment with Pluristem's PLX Cells

August 7, 2012

• Pfizer Announces Co-Primary Clinical Endpoints Not Met In Second Phase 3 Bapineuzumab Study In Mild-To-Moderate Alzheimer's Disease Patients Who Do Not Carry The Apoe4 Genotype
• Johnson & Johnson Announces Discontinuation of Phase 3 Development of Bapineuzumab Intravenous (IV) in Mild-to-Moderate Alzheimer's Disease
• Tensions Rise Between Teva CEO and CFO
• Isis Pharmaceuticals Rises on Strong 2Q Results
• Drug Companies Are Teaming With Academic Medical Centers to Create New Medicines, According to Tufts Center for the Study of Drug Development
• Mannkind 2Q Loss Narrows on Year-Ago Payment
• Pfizer Announces Resolutions with DOJ and SEC Related to Certain International Operations

August 8, 2012

• Pfizer Will Market Epipen Syringe in Japan
• Pfizer Gaucher Payment Pushes Protalix Into Profit
• Teva to Initiate Third Phase III Trial of Oral Laquinimod for the Treatment of Relapsing Remitting Multiple Sclerosis
• Lundbeck on Track to Meet Financial Expectations and Renew Its Product Portfolio to Secure Long-Term Growth
• Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer

August 9, 2012

• Novo Nordisk Increased Operating Profit by 31% in the First Half of 2012
• Ranbaxy Returns Sales Growth of 55% in Q2 2012 with Stronger Profitablity; Receives Approval for Multiple Value Added, Differentitated Products
• Hospira Announces U.S. Re-Launch Of Generic Oxaliplatin Injection
• Takeda and Millennium Termination of Ganitumab Phase III Study in Metastatic Pancreatic Cancer in Japan
• Lilly Revises 2012 Reported Guidance to Reflect Income from Early Payment of Amylin Obligations
• Bristol-Myers Squibb and AstraZeneca Complete Expansion of Diabetes Alliance Through Bristol-Myers Squibb's Acquisition of Amylin
• Bristol-Myers Squibb Completes Acquisition of Amylin Pharmaceuticals, Inc.

August 10, 2012

• PhRMA Statement on Flawed British Medical Journal Analysis
• K-V Pharmaceutical Use of Cash Collateral Approved by U. S. Bankruptcy Court
• Mylan Receives FDA OK for Lithium Carbonate Dose
• PharmAthene Receives FDA Notification On SparVax
• FDA Ends Orphan Exclusivity for Octapharma Drug Wilate
• Amgen Shutting Down Epogen Manufacturing

August 13, 2012

• Zoetis Files IPO Registration Statement
• Elan Announces Plan to Spin-Off Discovery Science And Neotope Biosciences to Shareholders
• Sun Pharma to Take Taro Private
• Stop Drug Trials in China: Lawyer
• Forest Laboratories Issues Open Letter to Shareholders
• InSite Vision & Merck Amend Payment Terms of AzaSite License Agreement
• Icahn Responds To Forest Labs Board
• Pfizer And Astrazeneca Enter Into Agreement For Over-The-Counter Nexium
• FDA Approves Vaccines for the 2012-2013 Influenza Season

August 14, 2012

• Shire CEO Says Company Nearing Decision on Move
• Octagon Research Solutions Acquired By Accenture PLC
• FDA Approves Vaccines for the 2012-2013 Influenza Season
• Share of Physicians Seeing iPad Reps Doubles between 2011 and 2012 - 65 Percent of ePharma Physicians Who See Reps Have Seen an iPad Rep
• Cortex Pharmaceuticals and Pier Pharmaceuticals Consummate Merger
• Boehringer Ingelheim Achieves Further Growth in First Half of 2012 ? Difficult Business Environment Expected for the Second Half of the Year
• Upsher-Smith Completes Acquisition of Proximagen Group plc
• Q2 2012: Merck Transformation Starts to Yield First Results
• AstraZeneca and Pfizer Enter Agreement for Over-the-Counter Nexium; AstraZeneca Raises 2012 Guidance
• Icahn Comments On Warning Letter Just Sent By FDA To Forest
• IMS Health Expands Suite of Syndicated, Web-based Analytics With Acquisition of PharmaDeals Ltd.
• Target Survey Shows Adult Americans May Avoid the Flu Shot Due to Fear of Needles

August 15, 2012

• Regulus Therapeutics Forms Strategic Alliance for Discovery, Development and Commercialization of microRNA Therapeutics with AstraZeneca
• USF Files Suit Over Research Patent Deal
• Bristol-Myers Squibb Announces Specialty Pharmacy Patient Management Programs For Sprycel® (dasatinib) Patients
• GlaxoSmithKline Reaches Agreement to Divest Majority of Classic Brands in Australia for £172m
• Array Biopharma Posts Smaller Fiscal 4Q Loss
• Watson Sues FDA Regarding Delay of Generic Actos Approval
• Carl Icahn Wins Seat On Forest Labs Board
• IMS Health Acquires TTC, Strengthening Pharma R&D Services Capabilities
• FDA Warns of Risk of Death from Codeine Use in Some Children Following Surgeries
• Latest Top 100 Drug Sales Data Released: Loss of Patent Protection Has Significant Effect

August 16, 2012

• Idenix Provides Update on IDX184 Clinical Development Program

August 17, 2012

• Pluristem Obtains Indian Phase II Trial Approval
• Biotech Firm Has Plans to Grow in Tucson
• Morphotek Set to Begin Production Near Philly

August 20, 2012

• Dainippon Sumitomo Pharma Announces Organizational Changes: Establishment of the ?DSP Cancer Institute?
• Dyax Corp. Creates COO Position and Expands Executive Roles
• Reckitt Benckiser Pharmaceuticals Inc. Announces FDA Approval of Two New Dosage Strengths of Suboxone Sublingual Film (C-III) for Maintenance Treatment of Opioid Dependence
• India's CRO Market Poised to Grow

August 21, 2012

• Inspiration Biopharmaceuticals Announces New Global Commercialization Agreements with Ipsen
• Latest Drug Sales Data: Loss of Patent Protection Has Significant Effect, According to Drugs.com
• Article Preview211 People Died in Six Months During Clinical Trials in India
• Indian Court to Hear Crucial Novartis Patent Case on Cut-Price Generic Drugs
• FDA Issues New Safety Alert on Reumofan Plus and Reumofan Plus Premium

August 22, 2012

• EpiCept Announces Resignation of CEO Jack Talley
• Abbott Cholesterol Drug Subject of False-Marketing Suit
• SEC Charges Former Array BioPharma Manager For Insider Trading
• SEC Fines Ex-Array Biopharma Manager $150K As Part of Insider-Trading Probe
• G2: the Big Sleep: One in 10 Britons Now Use Sleeping Pills Regularly, Costing the NHS Pounds 50m A Year.
• Mike Golic, ESPN Radio Personality and Former Philadelphia Eagle, Holds Pre-Season "Training Camp" for People With Type 2 Diabetes
• Existing Anti-Fungal Drug May Treat Cancer
• Merck KGaA Acquires Cell Culture Media Specialist Biochrom AG

August 23, 2012

• Pfizer and Mylan Team Up to Establish Exclusive Long-Term Strategic Collaboration to Drive Sustained Growth of Generics Business in Japan
• Gilead Terminates Cicletanine Trial; All Eyes Remain on Quad
• Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
• NICE: Breast Cancer Treatment Does Not Provide Enough Benefit for Patients to Justify its Cost

August 24, 2012

• Bristol-Myers Squibb Discontinues Development of BMS-986094, an Investigational NS5B Nucleotide for the Treatment of Hepatitis C
• Statement on FDA Decision Regarding Endo Citizen Petition and Approval of a Generic Formulation of Lidoderm
• GSK and Theravance Announce Completion of the Phase III Programme for Once-Daily LAMA/LABA (UMEC/VI) in COPD
• Synergy Pharmaceuticals Acquires FV-100 Shingles Drug From Bristol-Myers Squibb Company
• Agennix AG Announces Corporate Restructuring
• Hospira to Create 200 Jobs in N.C.
• Pluristem Begins Phase II Artery-Disease Clinical Trial

August 27, 2012

• Merck Provides Update on Cardiovascular Development Programs
• Idenix Provides Update on IDX19368 Development Program
• Pfizer Gets Consents From Debt Holders
• Teva Loses Lung Cancer Drug Patent Appeal

August 28, 2012

• Pascal Soriot Appointed Chief Executive Officer of AstraZeneca
• Depomed Licenses Acuform Patents to J&J Division

August 29, 2012

• Lilly Stops Phase III Development of Pomaglumetad Methionil For the Treatment of Schizophrenia Based on Efficacy Results
• Small Pharma Co. Solving Big Problems
• Hospira to Acquire Active Pharmaceutical Ingredient Manufacturing and R&D Facilities
• SEC Charges Eight in Georgia-Based Insider Trading Ring
• FDA Approves tbo-filgrastim for Severe Neutropenia in Certain Cancer Patients

August 30, 2012

• FDA OKs Afinitor Disperz for Child Brain Tumors
• Kyowa Hakko Kirin Announces Temporary Suspension of Patient Enrollment for Phase 3 Clinical Study of ARQ 197 (Tivantinib) in Combination with Erlotinib in Non-Small-Cell Lung Cancer Patients
• FDA OKs Afinitor Disperz for Child Brain Tumors
• Sunovion Pharmaceuticals Inc. to Acquire Elevation Pharmaceuticals, Inc.

August 31, 2012

• Monthly News Round Up - August 2012
• VLST Corporation Announces In-licensing Agreement with Pfizer for Anti-CD40 Monoclonal Antibody
• FDA Approves Ironwood, Forest Labs Bowel Drug
• Revatio (sildenafil): Drug Safety Communication - Recommendation Against Use in Children
• Geron Jumps on Analyst View of Cancer Drugs
• Bristol-Myers Squibb Initiates Voluntary Recall of 10 Lots of BiCNU (carmustine for injection) Due to the Potential for Overfill
• Johnson & Johnson Settles Risperdal Case for $181 Million